Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients with Ventilator Associated-pneumonia

ConditionVentilator-associated Pneumonia

Trial statusRecruiting

Trial phasePhase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorUniversity Hospital, Toulouse

About this trial

The main objective of this study is to compare the median exposures at pharmacokinetic equilibrium of the two modalities of administration: 4-hours infusion of ceftolozane-tazobactam at a dosage of 2 gram three times a day vs 1-hour infusion of 2 gram three times a day.

Eligibility criteria

Qualifiers

patients with ventilator associated-pneumonia to Pseudomonas aeruginosa

patients hospitalized in intensive care units

Pseudomonas aeruginosa susceptible to ceftolozane-tazobactam

Simplified Acute Physiological Score II (SAPS II () > 20

Disqualifiers

None

Trial design

Treatments tested in this trial

1 hour infusion
4 hours infusion

Treatment groups

80 Participants

are divided into 2 treatment groups

Sponsors and collaborators

University Hospital, Toulouse

Lead sponsor

Source ClinicalTrials.gov